Early antibody treatment, inflammation, and risk of post-COVID conditions

Post-COVID conditions (PCCs) are common and have significant morbidity. Risk factors for PCC include advancing age, female sex, obesity, and diabetes mellitus. Little is known about treatment, inflammation, and PCC. Among 882 individuals with confirmed SARS-CoV-2 infection participating in a randomi...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Kelly A. Gebo, Sonya L. Heath, Yuriko Fukuta, Xianming Zhu, Sheriza Baksh, Allison G. Abraham, Feben Habtehyimer, David Shade, Jessica Ruff, Malathi Ram, Oliver Laeyendecker, Reinaldo E. Fernandez, Eshan U. Patel, Owen R. Baker, Shmuel Shoham, Edward R. Cachay, Judith S. Currier, Jonathan M. Gerber, Barry Meisenberg, Donald N. Forthal, Laura L. Hammitt, Moises A. Huaman, Adam Levine, Giselle S. Mosnaim, Bela Patel, James H. Paxton, Jay S. Raval, Catherine G. Sutcliffe, Shweta Anjan, Thomas Gniadek, Seble Kassaye, Janis E. Blair, Karen Lane, Nichol A. McBee, Amy L. Gawad, Piyali Das, Sabra L. Klein, Andrew Pekosz, Evan M. Bloch, Daniel Hanley, Arturo Casadevall, Aaron A. R. Tobian, David J. Sullivan
Format:	Artigo
Sprog:	Inglês
Udgivet:	American Society for Microbiology 2023-10-01
Serier:	mBio
Fag:	COVID-19 COVID-19 serotherapy post-COVID condition (PCC) post-acute sequelae of COVID (PASC) interleukin-6 cytokines
Online adgang:	https://journals.asm.org/doi/10.1128/mbio.00618-23
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!